Clinical Trial

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma ForumSOUTH SAN FRANCISCO, Calif., March…

9 months ago

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Key findings support weekly induction of immune cell trafficking by Decoy20, a critical factor in effective cancer immunotherapyNEW YORK, March…

9 months ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage…

9 months ago

Pathos AI Doses First Patient in Phase 1b/2a Clinical Trial of Pocenbrodib, a CBP/p300 Inhibitor

CHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Pathos AI, (www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through…

9 months ago

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the…

9 months ago

Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product

Transaction is part of the Company’s new corporate strategy to become a revenue generating biotechWARRINGTON, Pa., March 20, 2025 (GLOBE…

9 months ago

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

Positive Interim Blinded Data Supports Advancement Toward Potential Pivotal Phase 3 StudyPHOENIX, March 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology…

9 months ago

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

 REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March…

9 months ago

Infinitopes Strengthens Board with Two Biotech Leaders to Advance Precision Immunotherapies into the Clinic

Visionary sector leaders Dan Menichella and Jo Brewer, PhD join as Non-Executive DirectorsBringing strengths in strategy, immuno-oncology science execution from bench to…

9 months ago

Landmark Study Explains Why Obesity Drugs Work Differently for Women and Men

Olio Labs Identifies Why Women Experience Stronger Side Effects from GLP-1 DrugsThe Company's AI-Powered Combination Design Engine (CoDE) Maps Biological…

9 months ago